


## No More Animal Testing--President Biden signs the Bill meeting Professor Niazi's recommendations

A Bill signed today allows waivers of animal testing for new drugs and biosimilars, a major shift in how the drug development with lower cost and better safety.

CHICAGO, ILLINOIS, UNITED STATES,
December 30, 2022 /
EINPresswire.com/ -- Press Release
Chicago, Illinois
28 December 2022
No More <u>Animal Testing</u>--President
Biden signs the Bill meeting Professor
Niazi's recommendations.



Leave Them Alone

Professor Sarfaraz Niazi, a strong proponent of animal rights, won today big as President Biden signed the <u>FDA Modernization Act 2.0</u>, which includes the Reducing Animal Testing Act removing the animal testing requirements in drug development, as proposed by Professor Niazi in a



No More Animal Testing of New Drugs and Biosimilars" www.niazi.com Science magazine contribution that he had shared with every member of the US Senate and the House to convince them of the scientific rationale and merit behind avoiding animal testing.

The Bill amends 21 U.S.C. § 355(i) to substitute the term "nonclinical tests" for the current "preexisting clinical tests

(including tests on animals)" and also amends Section 351(k)(2)(A)(i)(l)(bb) of the <u>Biosimilars</u> Price Competition and Innovation Act (BPCIA) to substitute "animal studies (including the assessment of toxicity)" with "non-clinical" testing defined as: "a test conducted in vitro, in silico, or chemico, or a non-human in vivo test and may include animal tests, or non-animal or human biology-based test methods, such as cell-based assays, microphysiological systems, or bioprinted or computer models."

Professor Niazi stated, "this is a major shift in how drugs will be developed with better confidence in their safety, particularly the biological drugs that have no pharmacology in animals. Applied to biosimilars, this will expedite their market entry and at a more affordable

cost; and with lesser safety risk by preventing developers from using animal toxicity studies to justify analytical differences that are more relevant."

The Reducing Animal Testing Act was first created by Senator Lujan of New Mexico, with whom Niazi had shared his writings; another Bill in the Senate is to remove the Interchangeability status of biosimilars by Senator Lee of Utah, where Professor Niazi had provided the supporting arguments.

"Now we have technologies that are more objective in testing the safety and efficacy of drugs; I am glad that our first milestone is achieved, and the other interchangeability redaction of biosimilars will arrive soon, leaving only the removal of clinical efficacy that has proven to be worthless. To make biological drugs affordable, we need to have a better understanding of science and not require testing, just for the abundance of caution," said Niazi Professor Niazi is a member of the College of Pharmacy, University of Illinois, Chicago, IL. He has pioneered biosimilars with several FDA approvals.

Novel351k, Inc released this news.

Contact: niazi@351k.com; www.niazi.com

Sarfaraz Niazi University of Illinois +1 312-297-0000 NIAZI@NIAZI.COM Visit us on social media:

Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/608779826

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.